2019

		Download
2019/01/16	Adocia confirms its financial calendar for 2019
2019/01/03	PR: Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas

2018

		Download
2018/12/20	Adocia announces its financial calendar for 2019
2018/10/23	Adocia Announces Third Quarter 2018 Financial Results
2018/10/11	Adocia informs about a civil action filed by Eli Lilly
2018/10/05	Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon
2018/09/26	Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD)
2018/09/05	Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes
2018/08/30	Adocia Announces Update to Second Arbitration Against Eli Lilly & Company
2018/08/21	Number of shares and voting rights of ADOCIA as of July 31, 2018
2018/08/08	American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly
2018/07/25	Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2018/07/18	Adocia Presents First Half 2018 Financial Results
2018/06/14	Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions
2018/06/05	Adocia to Participate in the Jefferies 2018 Global Healthcare Conference
2018/06/01	Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine
2018/05/02	Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao
2018/04/26	Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China.
2018/04/19	Adocia announces the release of its Reference Document for the year 2017
2018/04/16	Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes
2018/04/16	Adocia announces first quarter 2018 financial results: Cash position and revenue
2018/04/09	Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon
2018/03/19	ADOCIA announced its financial results for 2017 and its perspectives for 2018
2018/02/09	Adocia to Present at the 2018 BIO CEO & Investor Conference in New York
2018/02/06	Adocia Files Additional Arbitration Claims Against Eli Lilly & Company
2018/01/25	Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes
2018/01/08	Adocia announces its financial calendar for 2018
2018/01/04	Adocia announces expanded use of BioChaperone® beyond diabetes

2017

		Download
2017/12/06	Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes
2017/11/20	Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study
2017/10/11	Adocia announces financial results for the third quarter 2017
2017/09/05	Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes
2017/07/26	Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer
2017/07/19	Adocia presents first half 2017 financial results
2017/06/07	Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes
2017/06/06	Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes
2017/06/01	Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump
2017/06/01	Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon
2017/05/30	Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions
2017/05/30	Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York
2017/05/19	Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris
2017/04/18	Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016
2017/04/18	Adocia announces first quarter 2017 financial results
2017/04/13	Number of shares and voting rights of Adocia as of March 31, 2017
2017/03/21	ADOCIA confirms its eligibility for the PEA – PME
2017/03/13	Number of shares and voting rights of ADOCIA as of February 28, 2017
2017/03/07	ADOCIA announced its financial results for 2016 and its perspectives for 2017
2017/02/14	Adocia announces its revenue and cash position for 2016
2017/02/13	Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference
2017/01/27	Adocia to hold conference call on Monday January 30, 2017
2017/01/27	Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro
2017/01/25	Adocia to hold conference call providing an update on its programs
2017/01/19	Adocia announces the transformation of its business model to increase the value of its projects
2017/01/05	Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes
2017/01/04	Adocia announces its financial calendar for 2017

2016

		Download
2016/12/16	Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro
2016/11/10	Adocia to Participate in Upcoming Investor Conferences
2016/11/07	Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes
2016/10/27	Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100
2016/10/12	Adocia announces third quarter 2016 financial results
2016/09/22	Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region
2016/09/20	Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes
2016/09/19	Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET)
2016/09/08	Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting
2016/09/07	Adocia announces new BioChaperone program combining a basal insulin and GLP-1s
2016/08/25	Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer
2016/07/20	Adocia presents first half 2016 financial results
2016/07/05	Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2016/06/08	Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon
2016/06/06	Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions
2016/06/02	Adocia to Present at the Jefferies 2016 Global Healthcare Conference
2016/05/31	Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects
2016/05/13	Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris
2016/05/03	Adocia strengthens its BioChaperone Combo patent portfolio
2016/04/27	Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes
2016/04/14	Adocia announces first quarter 2016 results
2016/04/11	Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100
2016/04/11	Adocia announces the release of its Reference Document, for the year 2015
2016/03/25	ADOCIA confirms its eligibility for the PEA – PME
2016/03/21	Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board
2016/03/16	Annual Financial Results 2015
2016/03/14	Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
2016/02/16	ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015
2016/02/04	Adocia to Present at the 2016 Leerink Global Healthcare Conference
2016/01/29	Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects
2016/01/08	Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets

2015

		Download
2015/12/16	Adocia announces its financial calendar for 2016
2015/12/15	Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016
2015/12/11	Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100
2015/11/25	Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes
2015/11/19	Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region
2015/11/04	Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes
2015/10/13	ADOCIA Reports Third Quarter 2015 Financial Results
2015/10/06	Adocia et Lilly initient une étude de phase 1b évaluant l’insuline ultra rapide BioChaperone Lispro chez des patients diabétiques de type 1 utilisant une pompe à insuline
2015/09/30	Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes
2015/08/27	Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
2015/07/21	Adocia presents financial results for the first half of 2015 highlighting strong growth
2015/07/10	Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo
2015/06/26	Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
2015/06/15	Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices
2015/05/28	Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015
2015/05/26	Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA)
2015/05/04	Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014
2015/04/29	Adocia is now integrated into the EnterNext Tech 40 Index
2015/04/20	Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon
2015/04/14	Adocia announces first quarter 2015 results
2015/03/16	Adocia will present its 2014 annual results and its perspectives of growth during a conference call
2015/03/10	Adocia reports a strengthened cash position and intensifies clinical development
2015/03/05	Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly
2015/02/17	ADOCIA: annual revenue and net cash position for 2014
2015/02/10	Adocia: modification of the means allocated to the liquidity agreement
2015/02/05	Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet
2015/01/20	Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation
2015/01/09	Half year report on Adocia’s liquidity agreement with Kepler Capital Markets

2014

		Download
2014/12/29	ADOCIA announces its financial calendar for 2015
2014/12/22	ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow
2014/12/19	Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
2014/10/16	ADOCIA Announces Third-quarter Financial 2014 Results
2014/09/30	ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry
2014/09/09	Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes
2014/08/25	Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer
2014/07/24	Adocia Reports Operational and Financial Results for the First Half of 2014
2014/07/09	Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes
2014/06/24	ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only)
2014/06/16	ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only)
2014/06/10	Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300
2014/06/04	Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014
2014/05/27	Adocia initiates ADR program in the United States
2014/05/20	Adocia: PR BC Lispro Initiation of phase 2a
2014/05/19	Adocia Press Release Liquidity Agreement with Kepler
2014/05/06	Termination of Liquidity Agreement with DSF Markets
2014/04/10	Adocia: Ultra Fast Lispro Clinical Results
2014/04/10	Adocia: Revenue Q1 2014
2014/03/26	Gerard Soula Interview – La bourse et la vie (Transcript)
2014/03/20	Adocia: Annual results 2013
2014/03/17	Adocia: confirmation of positive clinical results Combo
2014/02/26	Positive Clinical Results for Combo
2014/02/10	Adocia: Annual revenue of EUR 5.6 M in 2013
2014/01/28	Adocia strengthens its diabetic foot ulcer patent portfolio
2014/01/20	Half year report on Adocia’s liquidity agreement at December 2013
2014/01/06	Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin

2013

		Download
2013/12/09	Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors
2013/11/13	Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog
2013/10/24	Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M
2013/10/19	Gérard Soula : interview by Gérald Bouchon, radio Lyon 1ère
2013/09/05	Activity and results for the first half of 2013
2013/07/29	Adocia reacquires exclusive development rights to ultra-fast acting insulin analog. Adocia and Lilly terminate collaboration
2013/07/15	Half Year report on Adocia’s Liquidity agreement with BIL Finance
2013/04/26	Release of 2012 Reference Document (French only)
2013/04/24	Q1 2013 revenues
2013/04/23	Liquidity agreement
2013/04/23	PR Suspension liquidity agreement
2013/03/18	Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency
2013/02/13	ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012
2013/01/07	Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences

2012

		Download
2012/10/30	Adocia announces the strong growth of its turnover
2012/10/22	Adocia is extending its intellectual property to new formulations of monoclonal antibodies
2012/10/01	EASD 2012 – 48th Annual Meeting of the European Association for the Study of Diabetes – 1-5 October 2012, Messe Süd, Berlin, Germany
2012/09/12	Bio India International Conference – 12-13 septembre 2012, Grand Hyatt, Mumbai, Inde
2012/09/07	DFSICON 2012 – 11th Annual Meeting of Diabetic Foot Society of India – 7-9 September 2012, Hyderabad, India
2012/09/03	Financial results and business report for the first half of 2012
2012/09/02	WUWHS 2012 – 4th Congress of the World Union of Wound Healing Societies – 2-6 September 2012, Yokohama, Japon
2012/06/13	Adocia announces a strengthened intellectual property on its lead project for its chronic wounds treatment
2012/05/30	Additional contribution to Liquidity Agreement with Dexia Securities France (French only)
2012/04/26	ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012
2012/04/23	ADOCIA reports positive phase II clinical results
2012/04/02	Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA
2012/03/15	Liquidity agreement with Dexia Securities France (French only)
2012/03/15	ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial…